Zika Virus Antiviral Compound Screening Data with NS4B Mechanism

A 5.5 KB dataset from figshare contains results from a phenotypic, cytopathic effect-based high-throughput screening campaign for Zika virus (ZIKV) inhibitors. The data, authored by Donghoon Chung and last updated in April 2026, details medicinal chemistry optimizations that led to novel benzamide compounds with EC50 values in the 40–400 nM range. These findings establish NS4B as a target for antiviral development.

Use Cases

• Training QSAR models based on compound potency (EC50) and cytotoxicity (CC50) data.
• Analyzing structure-activity relationships for benzamide-derived antiviral leads.
• Studying antiviral resistance mechanisms linked to mutations in the NS4B protein.
• Comparing inhibitor potency against reference compounds like NITD-008.

Strengths

• Potency data includes specific EC50 values (40–400 nM) and CC50 values (>50 µM).
• Data is derived from a high-throughput screening and medicinal chemistry optimization campaign.
• License is CC-BY-4.0, permitting open sharing and adaptation.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), indicating limited scope.

Provenance

Source

figshare, authored by Donghoon Chung.

Collection Method

Phenotypic, cytopathic effect-based high-throughput screening followed by medicinal chemistry optimization.

Time Range

null

Freshness

Last updated 2026-04-03 18:00:33; freshness should be verified.

Geography

null